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by-nc-nd/4.0/).Platelets are versatile cells e Critical roles in
hemostasis and thrombosis
Platelets are small anucleated blood cells, derived from
precursor megakaryocytes in bone marrow1,2 that play a
key role in vascular repair and hemostasis.2e4 Their major
role is to accumulate at sites of damaged blood vessels and
initiate clotting in order to prevent blood loss. Resting
platelets in the blood circulation of mammals are smooth
and discoid in shape. When the vessel wall becomes
injured, collagen and other subendothelial matrix proteins
are exposed and interact with receptors on the platelet
surface, resulting in a series of intracellular signaling
events and platelet activation.3e5 The activated platelets
then change their shape and adhere to the site of injury.
Recruitment of additional platelets to the damaged site
leads to platelet aggregation and platelet plug formation
(i.e. the first wave of hemostasis).4,5
The second wave of hemostasis is mediated by the
coagulation system, which can be activated by eitherrombosis and hemostasis. After
lso release their internalized pla
stically contribute to the prote
is) are then initiated via platele
iate cell-based thrombin gener
lassical second wave of hemos
in the interface between theextrinsic (tissue factor pathway) or intrinsic pathway
following vessel damage. The vital product of coagulation
cascades is thrombin, which converts fibrinogen to fibrin,
leading blood coagulation that further assists the formation
of a clot/hemostatic plug. Thrombin is also the most potent
platelet agonist that induces platelet activation, granule
release and platelet adhesion/aggregation. Thus, the sec-
ond wave of hemostasis significantly enforces the first wave
of hemostasis. On the other hand, following platelet acti-
vation, phosphatidylserine exposure occurs, which gener-
ates a negatively charged membrane surface that can host
coagulation factors and markedly increase thrombin gen-
eration.6 These intensive interactions between the first and
the second waves of hemostasis synergistically contribute
to the formation of a hemostatic plug.3,7,8
An interesting and recent discovery describes the
deposition of plasma fibronectin9,10 into the injured vessel
wall and initiating a “protein wave of hemostasis”11
(Fig. 1). This “protein wave” hemostasis occurs even
earlier than the classical “first wave of hemostasis”,vascular injury, plasma fibronectin quickly deposits onto the
sma fibronectin from their granules. These plasma and platelet
in wave of hemostasis. Platelet adhesion and aggregation (i.e.
t receptors and their ligands. Activated platelets also provide a
ation, which contributes to blood coagulation that is initiated
tasis). In a growing hemostatic plug/thrombus, the fibrin and
injured vessel wall and platelet plug.
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granule fibronectin (internalized from plasma fibronectin
via aIIbb3 integrin)12e15 may be also involved. However, the
importance of this new discovery in diseases including
possible plasma fibronectin transfusion in controlling
bleeding disorders, particularly those associated with
anticoagulant therapies requires further investigation.11 It
is notable that platelets contribute to all the aforemen-
tioned three waves of hemostasis, which may explain why a
decreased platelet count in blood (i.e. thrombocyto-
penia)16 usually causes bleeding disorders, such as auto-
immune thrombocytopenia (ITP) and fetal and neonatal
alloimmune thrombocytopenia (FNAIT).
Despite the vital role in hemostasis, platelet adhesion
and aggregation at inappropriate sites may lead to throm-
bosis and vessel occlusion. In both men and women, heart
attack and stroke are the leading cause of morbidity and
mortality worldwide3,17 and are caused by thrombosis in the
coronary or cerebral arteries.7,18 Thrombotic events may
also occur in the placenta which may lead to miscarriage.19
In addition to their important roles in thrombosis and he-
mostasis, platelets have several other functions including
acceleration of atherosclerosis,20e22 lymphatic vessel
development,23e25 aiding in tumor growth,26 destruction of
microorganisms27,28 and infected cells29,30 and modulation
of inflammation and immune responses.31e34 Thus, plate-
lets are versatile cells that play critical roles in multiple
human diseases.
Platelet aIIbb3 integrin and GPIba: The
abundant functional receptors and common
targeted antigens in immune mediated
thrombocytopenia
There are many receptors expressed on platelets which
maintain platelet physiological and pathological functions.
The two major platelet surface receptors are glycoprotein
(GP) IIbIIIa (aIIbb3 integrin) and the GPIb-IX complex, which
mediate platelet adhesion and aggregation.4,35,36 GPIba, of
the GPIb-IX complex, is a leucine rich repeat family pro-
tein, which is essential for platelet tethering and adhesion
to the injured vessel wall primarily through binding to
immobilized von Willebrand factor (VWF), particularly at
high shear stress.3,37,38 The interaction between GPIba and
VWF can deliver a signal to platelets, which subsequently
causes a conformational change in aIIbb3 integrin on the
platelet surface39 leading to fibrinogen (Fg) binding.40 Fg
cross-links adjacent platelets, leading to platelet aggrega-
tion and platelet plug formation. Although it has been
documented for more than a half century that Fg is
required for platelet aggregation, interestingly, recent
studies demonstrated that the formation of a hemostatic
plug and thrombus formation can occur independently of
VWF and Fg,12,41 but not aIIbb3 integrin.42 These findings
suggest that other unidentified ligands of aIIbb3 integrin
exist which can also mediate platelet aggregation, and
hemostatic plug/thrombus formation.5,7,42 This mechanism
and its significance in thrombosis and hemostasis is
currently under investigation.41e45
There are approximately 80,000 copies of aIIbb3 integrin
and 25,000 copies of GPIba on the surface of resting humanplatelets.46,47 It was previously documented that both
GPIba and the aIIb subunit of the aIIbb3 integrin are
exclusively expressed on platelets and their precursors,
while the b3 subunit of the aIIbb3 integrin is expressed on
many other cell types such as endothelial and endothelial
progenitor cells,48,49 microglia,50 astrocytes,51 sperm
cells52 and trophoblast cells of the placenta.53 The
expression of GPIba on endothelial cells (ECs) has been
demonstrated under certain conditions,54,55 however this
remains controversial.56 Within the last decade aIIb has
been shown to be expressed on early trophoblast cells of
the placenta,57 mast cells,58 embryonic stem cells59 and
hematopoietic stem cells (HSCs).60 Little is known about
the role aIIb plays in stem cells, however it is thought to
maintain HSC activity during embryonic development,61
although the exact function of aIIb in stem and mast cells
remain unclear.
In addition to their important physiological and patho-
logical roles in hemostasis and thrombosis, platelet aIIbb3
integrin and GPIba are the major targeted antigens in both
auto- and alloimmune thrombocytopenias (e.g. ITP and
FNAIT).62,63 Although the immunogenecity and the exact
mechanisms of immune response are still not well under-
stood, their abundant expression and significant amounts of
polymorphisms likely contribute to the pathogenesis of
these immune-mediated thrombocytopenias.Thrombocytopenia disorders
Thrombocytopenia refers to a decrease in the number of
circulating platelets in the blood. In healthy adults, the
normal range in circulating platelets is 150400  109/L
and a platelet count below this range may lead to severe
bleeding, where in some cases may be life threatening.31
The three major categories of thrombocytopenia are
immune-mediated, genetic deficiency-associated and
malignancy-associated. Immune-mediated thrombocyto-
penia can be further sub-classified into autoimmune or
alloimmune thrombocytopenia.33,64
Autoimmune thrombocytopenia is caused by a loss of
self-tolerance resulting in an abnormal immune response,
targeting one’s own platelets. Autoimmune thrombocyto-
penia is categorized into primary immune thrombocyto-
penia (ITP), drug-induced thrombocytopenia and infection
associated thrombocytopenia.65e67 ITP is the most common
with an incidence of 1e2.5 per 10,000 individuals68 and the
degree of thrombocytopenia can range from mild to se-
vere.62 It has been shown that both platelet destruction
and impaired platelet production may contribute to low
platelet counts, although the exact contributions by each
remain unclear.69 To date, autoantibodies are considered
to be the predominant effector in thrombocytopenia. In
adult ITP patients, approximately 70% of detectable
platelet autoantibodies are directed against aIIbb3 integ-
rin, and roughly 20%e40% have specificity for the GPIba
complex, or both.70 Interestingly, there is a subpopulation
of ITP patients who are thrombocytopenic but have no
detectable antibodies. One proposed explanation is that in
this group of patients, ITP is mediated by CD8þ T cells (i.e.
cytotoxic T-lymphocytes).71e73 On the other hand, it may
be that the current antibody detection systems are not
176 B. Vadasz et al.optimal and may be unable to detect some of the autoan-
tibodies that recognize conformation-dependent epitopes.
The conformations of these platelet antigens may be
changed during the anticoagulant treatment and sample
preparations, subsequently losing their binding sites for
some antibodies.74 This may be particularly important for
aIIbb3 integrin, since divalent cations play important roles
in maintaining integrin structure and function.75e79 Diva-
lent cation chelators (e.g. sodium citrate, and EDTA) in the
anti-coagulated blood may generate false negative results
and decrease the autoantibody detection.
Platelet clearance mediated by anti-platelet autoanti-
bodies typically result in platelet phagocytosis by Fcg-re-
ceptor bearing cells of the reticuloendothelial system (RES)
such as macrophages, and the majority of these opsonized
platelets are cleared in the spleen. However some ITP pa-
tients, particularly those with anti-GPIba antibodies who do
not respond well to treatments,80e83 may mediate platelet
clearance through an Fc-independent pathway,84,85 leading
to alternative sites of platelet clearance.86 A recent study
found that platelet desialylation87 may occur after anti-
body binding, particularly those platelets opsonized by
anti-GPIba antibodies.88 This mechanism leads to platelet
clearance in the liver via Ashwell-Morell receptors on he-
patocytes, which is fundamentally different from the
classical Fc-FcgR-dependent macrophage phagocytosis in
spleen.88 This discovery may be important not only in basic
research, but also for diagnosis and treatment of refractory
ITP (Nature Communications in revision).89,90 It is currently
unknown whether this novel Fc-independent platelet
clearance pathway also occurs in fetuses and contributes to
FNAIT.ITP in pregnancy and other neonatal
thrombocytopenias
Expecting mothers with pre-existing ITP have been less well
studied and as such the effect of the disease on neonates is
controversial.91,92 Neonatal thrombocytopenia in mothers
with ITP cannot be predicted by history or platelet count,
however an affected older sibling is a reliable risk factor in
subsequent pregnancies.93 Despite being rare and less of a
clinical concern, some cases of neonates born to mothers
with ITP have been associated with extensive hemorrhage
and fetal death.94,95 Neonatal thrombocytopenias which
are not due to anti-platelet antibodies are generally asso-
ciated with chronic fetal hypoxia, as seen in mothers with
pregnancy-induced hypertension, diabetes or intrauterine
growth restriction (IUGR).96 The mechanism of non-
antibody mediated forms of neonatal thrombocytopenia is
thought to be reduced megakaryopoiesis97 and cases are
usually mild since neonate platelet count normally resolves
within 10 days.98
Alloimmune thrombocytopenia is due to alloantibody-
mediated platelet depletion and develops when an im-
mune response is generated following exposure to allogenic
platelets. This can occur after transfusion of platelets from
allogenic donors, termed post-transfusion purpera (PTP) or
during pregnancy following maternal exposure to paternal
alloantigens on fetal platelets, termed fetal and neonatal
alloimmune thrombocytopenia (FNAIT).99 FNAIT is similar tothe more common condition hemolytic disease of the fetus
and newborn (HDFN) where maternal alloantibodies target
antigens on fetal red blood cells. In contrast to HDFN that
occurs following antigen exposure in the previous preg-
nancy, FNAIT may develop in the first pregnancy in up to
50% of all cases,100,101 making diagnosis and treatment
more difficult.Fetal and neonatal alloimmune
thrombocytopenia
FNAIT is caused by fetal platelet destruction by maternal
alloantibodies developed during pregnancy.102,103 Harring-
ton et al were the first to formally describe neonatal
thrombocytopenia in 1953, where two infants were born
with significantly decreased platelet counts, delivered from
mothers without ITP.104 Although serological techniques
were not available at the time, this was the first identifi-
cation and report describing what we now know as FNAIT.
Shulman et al105 first identified that maternal alloimmuni-
zation and antibodies targeting platelet antigens was the
reason for platelet destruction in neonates with the dis-
ease. Today FNAIT is the most common cause of severe
thrombocytopenia in live born neonates100 and accounts for
up to 40% of all neonates admitted into the neonatal
intensive care unit.106 FNAIT is now recognized as a critical
complication in pregnancy with severe and adverse out-
comes. Due to the life threatening nature of FNAIT, there
are ethical concerns in performing basic research on human
fetuses and neonates with the disease. The use of animal
models in FNAIT research will surely help decode the
complexity of this disease and may lead to treatment in
humans.
FNAIT is also the most common cause of intracranial
hemorrhage (ICH) in full-term infants,107 which is the most
severe clinical complication of FNAIT and may lead to
neurological impairments or death.95,108e110 ICH occurs at a
rate of 10%e20% in neonates born with FNAIT and has fatal
consequences in approximately 5% of documented
cases.102,111 An ICH can also occur in utero as early as week
14 of pregnancy in fetuses affected by FNAIT,112 suggesting
that early diagnosis and management are necessary to
prevent morbidity and mortality. The recurrence rate of a
subsequent pregnancy affected by FNAIT is close to 100% in
antigen positive siblings and they usually have a similar or
more severe form of thrombocytopenia.109,113 Therefore,
the only established biomarker for severity of the disease is
if a previous sibling presents with ICH.113,114 Interestingly,
in some cases ICH is independent of the severity of
thrombocytopenia,113,115 indicating that other mechanisms
aside from low platelet count likely contribute to bleeding
in the brain as seen in some neonates.
Several large studies have shown an incidence of FNAIT
between 1 and 1.5/1000 live births.106,116e118 However,
these reports do not include the rate of miscarriage asso-
ciated with the disease, therefore FNAIT may be much
more prevalent than previously thought. Although it has
been reported by several groups,101,119,120 the rate of
miscarriage in affected pregnant women has not been
adequately studied. One explanation for this is that rare
human platelet antigens (HPAs) may induce severe FNAIT
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and frequency of reported cases of FNAIT in humans.
In healthy human fetuses, the platelet count reaches
approximately 300  109/L by 30e35 weeks of gestation121
and thrombocytopenia in the fetus or neonate has been
defined as a platelet count less than 150  109/L, however
FNAIT can cause severe thrombocytopenia where platelet
counts are often below 20  109/L.120 Alloantibodies
generated in the mother are transported across the
placenta via the neonatal Fc receptor (FcRn) during preg-
nancy and enter fetal circulation and opsonize platelets
and mediates clearance122,123 (Fig. 2). It is thought that
platelet destruction in FNAIT is similar to that in ITP. Allo-
antibody bound platelets interact with Fc receptors on
macrophages through the Fc fragment of IgG, resulting in
clearance of the antibody-bound platelets by the RES sys-
tem in the spleen.124 However, some ITP patients with an-
tibodies targeting GPIba may have Fc-independent platelet
clearance,86 which may also be occurring in FNAIT patients.
It is currently unclear whether there are significant differ-
ences between adult and fetal/neonatal platelet clearance
mechanisms.Gene polymorphisms and platelet alloantigens
in FNAIT
In 1990, the Platelet Serology Working Party of the Inter-
national Society of Blood Transfusion (ISTB) established a
nomenclature for platelet antigens.125 They classified
platelet antigens as HPAs, where each platelet antigen is
numbered based on date of discovery and the more com-
mon alleles are ordered in alphabetical pairs based on
frequency e ‘a’ for the common allele and ‘b’ for the rare
allele.126 All HPAs result in a single amino acid substitution
except for HPA-14w where the antigen is a result of a one
amino acid deletion.127 The database of all immunizingFigure 2 Pathogenesis of fetal and neonatal alloimmune thromb
Johnson J and Rand M, Baillieres Best Pract. Res Clin Haematol, 20
Spring CM, Freedman J and Ni H, Blood, 2010, 116 (18), 3660e366HPAs that have caused at least one case of FNAIT can be
found at http://www.ebi.ac.uk/ipd/hpa/table2.html. To
date there are 36 HPAs on six platelet surface proteins that
have been discovered and may lead to FNAIT.128 Of these,
18 are located on integrin b3 subunit (including HPAs 1a, 1b,
1c, 4a, 4b, 6bw, 7b, 7c, 8bw, 10bw, 11bw, 14bw, 16bw,
17bw, 19bw, 21bw, 23bw and 26bw), 8 are located on the
aIIb subunit (HPAs 3a, 3b, 9bw, 20bw, 22bw, 24bw, 27bw
and 28bw), 5 on integrin a2 (HPAs 5a, 5b, 13bw, 18bw and
25bw), 2 on GPIba (HPAs 2a and 2b), 1 on GPIbb (HPA 12bw)
and 2 on CD109 (HPAs 15a and 15b). 26 HPAs are caused by
bi-allelic polymorphisms and two HPAs are due to tri-allelic
polymorphisms.129
Despite the existence of multiple platelet antigens, only
few are responsible for the majority of reported cases of
FNAIT. Incompatibility of HPA-1 (a leucineeproline differ-
ence at residue 33 of the b3 integrin130) accounts for
approximately 75%e85% of cases in Caucasians.131 Although
FNAIT due to HPA-1a incompatibility is very rare in African
and Asian populations,132,133 irrespective of race, HPAs in
the b3 integrin subunit account for the vast majority of
reported cases.134e136 It is interesting that certain poly-
morphisms are found much more abundantly in certain
populations than others. The HPA-4 polymorphism, also
located on the subunit b3 integrin, resides on residue 143
and is more prevalent in the Asian population, as well as
HPA-21bw.137 In addition, HPA-6bw is a more common
polymorphism to the Finnish population that causes
FNAIT.138 HPA-5 is located on integrin a2 subunit of the
collagen receptor and is the second most common antigen
causing FNAIT accounting for 10%e15% of all cases.139 The
reported incidence of FNAIT due to HPA-2 on GPIba is
rare.140,141 However, it is currently unknown whether pro-
thrombotic events are induced by anti-GPIba antibodies in
the placenta,19 which may cause miscarriage and mask the
reported incidence in humans. FNAIT caused by HPA-2 may
also be rare due to the lower immunogenicity of thisocytopenia (FNAIT). This figure is adapted from Blanchette VS,
00, 13(3): 365e90 and Chen P, Li C, Lang S, Zhu G, Reheman A,
8.
178 B. Vadasz et al.leucine repeat family protein that may stimulate a weaker
immune response in women.86
Interestingly, 5 out of 8 HPAs on the aIIb subunit are
located in very close proximity within the calf-2 domain,
including the most common aIIb antigens HPA-3a and HPA-
9bw. These HPAs only account for 2%e5% of all cases of
FNAIT,106,131 however they are typically involved in more
severe cases of FNAIT.142,143 HPA-3b and HPA-9b are in a
linkage disequilibrium, explained by the fact that they are
located only 19 base pairs apart.129 HPA-22bw resides on
the b-propeller domain, close to the ligand-binding site,
which may interfere with fibrinogen and other ligand
binding and cause severe bleeding in affected neonates.144
Both polymorphisms themselves and alloantibody binding
may affect hemostasis/thrombosis. HPA-13w on the a2
integrin and both HPA-1b and HPA-21bw on the b3 integrin
subunit have also been identified as HPAs that interfere
with receptor function.145,146 However the extent to which
various HPAs contribute to hemorrhagic or thrombotic risk
remains to be determined.147
Glycoprotein IV (CD36) deficiency occurs in 3%e5% of
individuals of African or Asian ancestry. It is a member of
the class B scavenger receptor family of proteins expressed
on platelets, red blood cells, endothelial cells, monocytes
and macrophages.148 Mothers who lack CD36 are at risk of
becoming immunized if exposed to the protein by trans-
fusion or pregnancy.149 It is interesting that affected neo-
nates have a severely decreased platelet count without
solid evidence of other tissue damage despite CD36 being
expressed on endothelial cells and other blood cells.148
Immunization against CD36 is termed ‘Nak’ isoantibody
generation. Since CD36 is expressed on multiple cells, it
does not have HPA nomenclature.150Mechanisms of alloantibody generation in
FNAIT
FNAIT is thought to be initiated by fetal
platelet alloantigens that are inherited from the father but
absent in the mother. The mechanism of exposure of the
mother to fetal alloantigens is not well understood. Similar
to HDFN, immunization may occur as a result of fetoma-
ternal hemorrhage during parturition.116,151 Since FNAIT
often occurs during the first pregnancy, fetal platelets may
“leak” into the maternal circulation and initiate an immune
response. The smaller size and greater mobility of platelets
compared to red blood cells may attribute to FNAIT
development in the first pregnancy as compared to HDFN. It
has been demonstrated that b3 integrin is expressed on
human trophoblast cells of the placenta,57,152 suggesting
that an immune response may be generated independently
of platelets but via a maternal immune response against b3
integrins on trophoblast cells. In addition, b3 integrin is also
expressed on spermatozoa,52,153 therefore suggesting that
women may become immunized with preconceptional
exposure.
When platelet antigens are exposed to the maternal
circulation, they are processed by antigen presenting cells
and subsequently presented to T helper lymphocytes
similar to other foreign antigens.99,153e157 T cells may then
stimulate B cells to become activated and differentiate intoplasma cells and secrete antigen-specific IgG antibodies.
Macrophages themselves may also directly stimulate the
differentiation of B cells to plasma cells.158 Interestingly,
not all mothers with incompatible fetuses will develop
FNAIT; prospective studies indicate only approximately 10%
of women with an HPA-1a incompatible fetus will become
immunized during pregnancy.116,159,160 The most plausible
explanation for this may be the strong association between
the human leucocyte antigen (HLA) class II DRB3*0101 and
DRB4*0101 alleles and HPA-1a alloantibody generation.155
The DRB3 allele has also been demonstrated to have bind-
ing affinity for HPA-1a but not HPA-1b.154 This implies that
specific maternal antigen presentation pathway and a
specific genetic background may be involved in fetal anti-
gen alloimmunization. In addition, co-existing viral or
bacterial infections may also enhance the maternal im-
mune response against fetal platelet antigens.156
Once antibodies against fetal platelet alloantigens are
generated in the mother, they can enter fetal circulation
via FcRn122 and cause platelet opsonization and clear-
ance.123 It is thought that platelet destruction in FNAIT is
similar to that in ITP. Alloantibody-bound platelets interact
with Fc receptors on macrophages through the Fc fragment
of IgG, resulting in clearance of the antibody-bound
platelets by the RES system in the spleen.124 However,
some ITP patients with antibodies targeting GPIba may
have Fc-independent platelet clearance,86 which may also
be occurring in FNAIT patients. It is currently unclear
whether there are significant differences between adult
and fetal/neonatal platelet clearance mechanisms.Therapies and management of FNAIT
Although there have been significant advancements in the
diagnosis and management of FNAIT within the past
decade, existing therapies are currently limited and pro-
phylactic treatments are lacking. FNAIT is a life-
threatening disease that may occur during the first preg-
nancy and antenatal management is challenging but
necessary. Since there is currently no screening procedure
in practice, diagnosis occurs after the delivery of a symp-
tomatic child.161 Several treatments including intravenous
immunoglobulin G (IVIG), corticosteroids and fetal and
neonatal platelet transfusions have been used to manage
FNIAT,162 however antenatal treatment has not been stan-
dardized.163 Although in utero platelet transfusions may be
effective in some FNAIT patients, most centers have
abandoned this technique due to its invasiveness and due to
the high risk of fetal loss.161,164 It is notable that recent
studies in murine models suggested that neither platelets
nor fibrin clots are essential for hemostasis in fetuses,165,166
therefore in utero fetal platelet transfusion may be less
important. However, platelet transfusion after birth has
been demonstrated to be very beneficial for neo-
nates.120,167 IVIG has been used to treat FNAIT albeit with
varying results.118,168 IVIG is pooled from the plasma of
healthy donors; it is expensive and in limited supply. There
are also risks of transmitting blood born pathogens with
administration of IVIG and it is often not well tolerated in
pregnant women.169 Recent clinical studies suggest a
combination of IVIG and corticosteroids is the most
Platelets and platelet alloantigens 179effective treatment, specifically when corticosteroids are
administered during the last trimester.170
Postnatal therapeutic options depend on the severity of
thrombocytopenia, since severe bleeding and ICH often
occur in neonates with platelet counts less than 20  109/
L.170 Platelet transfusions are the first line of therapy in
neonates with low platelet counts. Fortunately, random
donor platelets, even when incompatible, are frequently
effective either as sole treatment of FNAIT167,171 or when
administered together with IVIG. This is of significance
since matched platelets may not be available and obtaining
washed maternal platelets may not be possible in certain
cases. The challenge for effective therapy and manage-
ment is not only due to FNAIT occurring in the first preg-
nancy, rather it is due to a shortage of knowledge, which
requires research and animal models of this disease.
Animal models of FNAIT
Given the ethical difficulties in performing basic research
on human fetuses and neonates, animal models are essen-
tial to improve our understanding of the pathogenesis and
treatment of FNAIT. Previously we established the fist ani-
mal model of FNAIT, while other animal models have been
generated in order to study immune
thrombocytopenia.73,172e177 These include mouse models
such as (NZW  BXSB) F1 mice173 that develop lupus
nephritis, myocardial infarction, and thrombocytopenia;
and an immunodeficient SCID mouse/human chimera
model, in which human cord blood cells or splenocytes from
ITP patients were implanted into SCID mice.174 Other ani-
mal models such as murine,178,179 rat,175 dog,176 and ba-
boon177 have been studied, which were generated by
injection of anti-b3 integrin antibodies. In models of
alloimmune thrombocytopenia, genetically or chemically
modified anti-HPA-1a competitive antibodies (B2G1 and
SZ21) have been demonstrated to be able to block anti-
HPA-1a antibodies binding to HPA-1a-positive platelets in
murine models, suggesting their therapeutic poten-
tial.180,181 These models provide important information for
gaining a better understanding of the antibody-mediated
macrophage phagocytosis and the role of IVIG, which shed
light on the mechanisms of platelet destruction in FNAIT.
However, they provide little information to our under-
standing of the maternal immune responses causing FNAIT
or how pathogenic antibodies affect the fetus throughout
development.
Previous experiments from our laboratory have demon-
strated b3 integrin deficient (b3/) mice generate anti-
bodies when transfused with wild type (WT) platelets. After
immunized b3/ females were bred with WT males,
thrombocytopenia and ICH were observed in the hetero-
zygote pups. We also examined the role of FcRn in FNAIT via
combined deficiencies of b3/ and FcRne/e mice.122
Furthermore, we established a model of FNAIT mediated
by anti-GPIba antibodies.19
Lessons learned from animal models of FNAIT
Prior to establishing a murine model of FNAIT, the process
of the maternal immune response to fetal platelet antigenswas largely unknown. Although in clinical cases, mothers
usually generate antibodies against one specific site on the
integrin; our animal models have the advantage in that they
generate anti-platelet antibodies which are capable of
targeting multiple epitopes on platelet receptors as seen in
some cases.128 In addition, there are 18 alloantigens
(approximately half of all HPAs) located throughout the b3
integrin subunit (from the N-terminus to the C-terminus of
the extracellular domain), which are capable of eliciting an
immune response. Therefore the study of the immune
response against the entire b3 integrin subunit is of
importance to the understanding of FNAIT that are medi-
ated by different anti-HPA antibodies.
Our first model was established by transfusing female b3
deficient mice with WT platelets.153 These immunized fe-
male mice were then bred with WT male mice, to generate
a heterozygous fetus. Antibodies from the maternal circu-
lation cross the placenta via the FcRn and bind to fetal
platelets, leading to bleeding symptoms.122 Some mothers
underwent miscarriage and did not deliver pups, while
other pups were delivered stillborn. The severity of fetal
symptoms is correlated with the antibody titers in the
maternal circulation. Both IgG1 and IgG2a antibodies were
detected in the maternal serum, indicating that both T-
helper 1 (Th1) and Th2-like immune responses exist.
Therapeutic administration of IVIG to immunized mothers
decreased antibody titers in both mothers and neonates,
however, no anti-idiotype activity of IVIG was found in this
model.
Alloantibodies may have other roles in the pathogenesis
of FNAIT besides the destruction of fetal platelets. ICH has
been observed in some patients whose platelet counts are
within the normal range.115 Our lab demonstrated that anti-
b3 antibodies generated in our model of FNAIT can cross
react with aVb3 integrin on angiogenic endothelial cells
in vivo, leading to impaired angiogenesis.182 Neonates born
to our model of anti-b3 mediated FNAIT present with ICH
and decreased blood vessel density in both their brains and
retinas. However neonates from the anti-GPIba model of
FNAIT did not show any evidence of bleeding in the brain or
decreased vascular density. In vitro studies with anti-HPA-
1a antibodies demonstrate inhibited proliferation and
network formation of human umbilical vein endothelial
cells (HUVECs). Interestingly, anti-b3 antibodies injected
into aIIbe/e neonates induce ICH, suggesting that ICH may
develop independently of thrombocytopenia. Therefore,
ICH likely results from interference of aVb3 integrin on ECs
by antibodies in FNAIT, leading to impairments in blood
vessel development in the brains of fetuses and
neonates.182,183
Miscarriage is a devastating outcome of FNAIT, however
the incidence and mechanism of miscarriage has not been
adequately studied. Therefore, an animal model of FNAIT is
particularly useful in examining the pathophysiological
mechanism of miscarriage. In contrast to the 20%e40%
prevalence of anti-GPIba antibodies in patients with im-
mune thrombocytopenia,67 there are few reported cases of
anti-GPIba FNAIT.140 Our laboratory has demonstrated in an
FNAIT animal model that anti-GPIba antibodies cause
spontaneous miscarriage,19 which may explain the low
frequency of anti-GPIba mediated FNAIT in humans.
Miscarriage may also account for the low frequency of other
180 B. Vadasz et al.rare antigens reported in FNAIT such as anti-aIIb mediated
FNAIT, however more studies are needed to confirm this
phenomenon.
Antenatal treatments such as IVIG and steroids have
been used to treat FNAIT, however the mechanisms of these
treatments are still not well understood and they are often
accompanied by side effects. Therefore, a safer and more
effective therapy remains to be developed. The FcRn has
been shown to be important in transplacental transfer of
IgG antibodies from mother to the fetus during preg-
nancy.122,184 However, it has been speculated that other
IgG associated proteins may also contribute for the trans-
port of IgG across the placenta, specifically in inflammatory
conditions. We have shown that in an animal model of
FNAIT, fetuses lacking the FcRn prevented the transfer of
pathogenic antibodies from the mothers.122 In addition,
targeting the FcRn with anti-FcRn antibody or IVIG ame-
liorates FNAIT. Prior to our discovery, it was previously
unknown whether FcRn independent IgG placental trans-
port plays a significant role in FNAIT, and whether this
pathway can be upregulated during inflammation or other
pathologies that occur in the placenta during FNAIT. How-
ever, in our animal models, we clearly demonstrated that
fetal but not maternal FcRn is required for all IgG placental
transport and required for induction of FNAIT.122
While infection in the pathogenesis of ITP has been
investigated,66 infection in FNAIT has not. In our mouse
model of FNAIT, injections of lipopolysaccharide (LPS)
(mimicking bacterial infection) or Poly I:C (mimicking viral
infection) was performed together with immunization of
WT platelet in GPIbae/e and b3/ mice. We found
enhanced antibody generation, more severe bleeding and
increased rates of miscarriage in these mice.156 This sug-
gests that bacterial or viral infection may enhance the
severity of FNAIT and also other alloimmune thrombocyto-
penias such as post-transfusion purpura (PTP). Control of
infection may be an important strategy during pregnancy to
attenuate FNAIT and PTP, and after pregnancy to prevent
miscarriage in subsequent pregnancies.Future treatments of FNAIT
Treating and preventing FNAIT is especially difficult
because of the severity of bleeding symptoms and also
because it may occur during the first pregnancy. However
results from a retrospective study indicate that FNAIT
occurring in the first pregnancy may be less common than
expected185 and that FNAIT may be treated prophylacti-
cally similar to HDFN. Antibody-mediated immune sup-
pression (AMIS) has successfully been used for prevention of
RhD immunization for the past 4 decades.186 Results from a
proof of concept study using our mouse model of FNAIT
suggest that the same principle may be applied for the
prevention of FNAIT. In our murine model of FNAIT, AMIS led
to a 90% reduction in anti-platelet antibodies in maternal
circulation, significantly elevated neonatal platelet counts
and vastly improved pregnancy outcomes.187 The idea of a
prophylactic approach in FNAIT is supported and deserves
further studies in clinical trials.
Therapeutics targeting the FcRn may be considered as a
useful therapyalternative to current treatments. Thedoseofanti-FcRn required to mediate therapeutic effects are much
lower than that of IVIG (at least 200-fold less), suggesting
that treatment with anti-FcRn antibody may be a more effi-
cient therapy.122 Anti-FcRn therapy would also be advanta-
geous, as it is not prepared from pooled human plasma (as is
the case for IVIG), thereby decreasing the chance of patient
exposure to blood born micropathogens as well as being a
more cost effective therapy. Therefore, the use of anti-FcRn
monoclonal antibody is promising as a future treatment for
this disease and deserves further clinical consideration. In
conclusion, further clinical studies on treatments are war-
ranted for FNAIT. It is also of significance to investigate the
possible differences of platelet function, the coagulation
system, and RES system between fetus and adult.Acknowledgments
The authors gratefully acknowledge Dr. Richard O. Hynes
and Dr. Jerry Ware and Dr. Zaviero M. Ruggeri for providing
the b3 integrin and GPIba deficient mice. This work was
supported by Canadian Institutes of Health Research (MOP
68986, MOP 119551, MOP 97918, and 119540), Heart and
Stroke Foundation of Canada (Ontario), and Canadian Blood
Services/Canadian Institutes of Health Research operating
grant, Equipment Funds from St. Michael’s Hospital, Cana-
dian Blood Services and Canada Foundation for Innovation.
B. Vadasz is a recipient of graduate fellowships from the
Department of Laboratory Medicine and Pathobiology,
University of Toronto and of the Queen Elizabeth II Ontario
Graduate Scholarship. I. Yougbare´ is a recipient of the Ca-
nadian Blood Services postdoctoral fellowship. D. Zdravic is
a recipient of Canadian Blood Services graduate fellowship.
J. Li is a recipient of Laboratory Medicine and Pathobiology
Departmental Fellowship, University of Toronto. C. Li is a
recipient of Laboratory Medicine and Pathobiology
Departmental Fellowships and of the Connaught Scholar-
ship, University of Toronto. We acknowledge Alexandra
Marshall for her contribution to Figure 1.References
1. Junt T, Schulze H, Chen Z, et al. Dynamic visualization of
thrombopoiesis within bone marrow. Science. 2007;317:
1767e1770.
2. Wang Y, Andrews M, Yang Y, et al. Platelets in thrombosis and
hemostasis: old topic with new mechanisms. Cardiovasc
Hematol Disord Drug Targets. 2012;12:126e132.
3. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8:
1227e1234.
4. Ni H, Freedman J. Platelets in hemostasis and thrombosis:
role of integrins and their ligands. Transfus Apher Sci. 2003;
28:257e264.
5. Jackson SP. The growing complexity of platelet aggregation.
Blood. 2007;109:5087e5095.
6. Roberts HR, Hoffman M, Monroe DM. A cell-based model of
thrombin generation. Semin Thromb Hemost. 2006;32(suppl
1):32e38.
7. Reheman A, Xu X, Reddy EC, Ni H. Targeting activated
platelets and fibrinolysis: hitting two birds with one stone.
Circ Res. 2014;114:1070e1073.
8. Clemetson KJ. Platelets and primary haemostasis. Thromb
Res. 2012;129:220e224.
Platelets and platelet alloantigens 1819. Ni H, Yuen PS, Papalia JM, et al. Plasma fibronectin promotes
thrombus growth and stability in injured arterioles. Proc Natl
Acad Sci U S A. 2003;100:2415e2419.
10. Ni H. Unveiling the new face of fibronectin in thrombosis and
hemostasis. J Thromb Haemost. 2006;4:940e942.
11. Wang Y, Reheman A, Spring CM, et al. Plasma fibronectin
supports hemostasis and regulates thrombosis. J Clin Invest.
2014;124:4281e4293.
12. Ni H, Denis CV, Subbarao S, et al. Persistence of platelet
thrombus formation in arterioles of mice lacking both von Wil-
lebrand factor and fibrinogen. J Clin Invest. 2000;106:385e392.
13. Ni H, Papalia JM, Degen JL, Wagner DD. Control of thrombus
embolization and fibronectin internalization by integrin alpha
IIb beta 3 engagement of the fibrinogen gamma chain. Blood.
2003;102:3609e3614.
14. Xu X, Wu J, Zhai Z, et al. A novel fibrinogen Bbeta chain
frameshift mutation in a patient with severe congenital
hypofibrinogenaemia. Thromb Haemost. 2006;95:931e935.
15. Zhai Z, Wu J, Xu X, et al. Fibrinogen controls human platelet
fibronectin internalization and cell-surface retention.
J Thromb Haemost. 2007;5:1740e1746.
16. Harrington WJ, Minnich V, Hollingsworth JW, Moore CV.
Demonstration of a thrombocytopenic factor in the blood of
patients with thrombocytopenic purpura. J Lab Clin Med.
1951;38:1e10.
17. Heart attack and stroke: men vs. women. For both men and
women, cardiovascular disease is the leading cause of death.
But their risks and symptoms can differ. Harv Heart Lett: from
Harvard Medical School. 2014;24:1e7.
18. Yang Y, Shi Z, Reheman A, et al. Plant food delphinidin-3-
glucoside significantly inhibits platelet activation and throm-
bosis: novel protective roles against cardiovascular diseases.
PloS One. 2012;7:e37323.
19. Li C, Piran S, Chen P, et al. The maternal immune response to
fetal platelet GPIbalpha causes frequent miscarriage in mice
that can be prevented by intravenous IgG and anti-FcRn
therapies. J Clin Invest. 2011;121:4537e4547.
20. Murphy AJ, Bijl N, Yvan-Charvet L, et al. Cholesterol efflux in
megakaryocyte progenitors suppresses platelet production
and thrombocytosis. Nat Med. 2013;19:586e594.
21. Podrez EA. Bad versus good cholesterol in the bone marrow.
Nat Med. 2013;19:541e543.
22. Ni H. The platelet “sugar high” in diabetes. Blood. 2012;119:
5949e5951.
23. Hess PR, Rawnsley DR, Jakus Z, et al. Platelets mediate
lymphovenous hemostasis to maintain blood-lymphatic
separation throughout life. J Clin Invest. 2014;124:273e284.
24. Bertozzi CC, Schmaier AA, Mericko P, et al. Platelets regulate
lymphatic vascular development through CLEC-2-SLP-76
signaling. Blood. 2010;116:661e670.
25. Herzog BH, Fu J, Wilson SJ, et al. Podoplanin maintains high
endothelial venule integrity by interacting with platelet
CLEC-2. Nature. 2013;502:105e109.
26. Coupland LA, Parish CR. Platelets, selectins, and the control
of tumor metastasis. Semin Oncol. 2014;41:422e434.
27. Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates
neutrophil extracellular traps to ensnare bacteria in septic
blood. Nat Med. 2007;13:463e469.
28. Youssefian T, Drouin A, Masse JM, Guichard J, Cramer EM.
Host defense role of platelets: engulfment of HIV and
Staphylococcus aureus occurs in a specific subcellular
compartment and is enhanced by platelet activation. Blood.
2002;99:4021e4029.
29. McMorran BJ, Wieczorski L, Drysdale KE, et al. Platelet factor
4 and duffy antigen required for platelet killing of Plasmo-
dium falciparum. Science. 2012;338:1348e1351.
30. Yeaman MR. Platelets: at the nexus of antimicrobial defence.
Nat Rev Microbiol. 2014;12:426e437.31. Semple JW, Italiano Jr JE, Freedman J. Platelets and the
immune continuum. Nat Rev Immunol. 2011;11:264e274.
32. Mantovani A, Garlanda C. Platelet-macrophage partnership in
innate immunity and inflammation. Nat Immunol. 2013;14:
768e770.
33. Li C, Li J, Li Y, et al. Crosstalk between platelets and the
immune system: old systems with new discoveries. Adv
Hematol. 2012;2012:384685.
34. Yang H, Lang S, Zhai Z, et al. Fibrinogen is required for
maintenance of platelet intracellular and cell-surface P-
selectin expression. Blood. 2009;114:425e436.
35. Ruggeri ZM. Mechanisms initiating platelet thrombus forma-
tion. Thromb Haemost. 1997;78:611e616.
36. Jackson SP. Arterial thrombosis e insidious, unpredictable
and deadly. Nat Med. 2011;17:1423e1436.
37. Lei X, Reheman A, Hou Y, et al. Anfibatide, a novel GPIb
complex antagonist, inhibits platelet adhesion and thrombus
formation in vitro and in vivo in murine models of thrombosis.
Thromb Haemost. 2014;111:279e289.
38. Ni H, Ramakrishnan V, Ruggeri ZM, Papalia JM, Phillips DR,
Wagner DD. Increased thrombogenesis and embolus formation
in mice lacking glycoprotein V. Blood. 2001;98:368e373.
39. Xiao T, Takagi J, Coller BS, Wang JH, Springer TA. Structural
basis for allostery in integrins and binding to fibrinogen-
mimetic therapeutics. Nature. 2004;432:59e67.
40. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the
platelet membrane glycoprotein IIb.IIIa complex during
platelet activation. J Biol Chem. 1985;260:11107e11114.
41. Reheman A, Yang H, Zhu G, et al. Plasma fibronectin deple-
tion enhances platelet aggregation and thrombus formation in
mice lacking fibrinogen and von Willebrand factor. Blood.
2009;113:1809e1817.
42. Yang H, Reheman A, Chen P, et al. Fibrinogen and von Wil-
lebrand factor-independent platelet aggregation in vitro and
in vivo. J Thromb Haemost. 2006;4:2230e2237.
43. Dunne E, Spring CM, Reheman A, et al. Cadherin 6 has a
functional role in platelet aggregation and thrombus forma-
tion. Arterioscler Thromb Vasc Biol. 2012;32:1724e1731.
44. Reheman A, Tasneem S, Ni H, Hayward CP. Mice with
deleted multimerin 1 and alpha-synuclein genes have
impaired platelet adhesion and impaired thrombus forma-
tion that is corrected by multimerin 1. Thromb Res. 2010;
125:e177e183.
45. Reheman A, Gross P, Yang H, et al. Vitronectin stabilizes
thrombi and vessel occlusion but plays a dual role in platelet
aggregation. J Thromb Haemost. 2005;3:875e883.
46. Modderman PW, Admiraal LG, Sonnenberg A, von dem
Borne AE. Glycoproteins V and Ib-IX form a noncovalent
complex in the platelet membrane. J Biol Chem. 1992;267:
364e369.
47. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS,
Jordan RE. Analysis of GPIIb/IIIa receptor number by quanti-
fication of 7E3 binding to human platelets. Blood. 1996;88:
907e914.
48. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular
integrin alpha v beta 3 for angiogenesis. Science. 1994;264:
569e571.
49. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha
v beta 3 antagonists promote tumor regression by inducing
apoptosis of angiogenic blood vessels. Cell. 1994;79:
1157e1164.
50. Welser-Alves JV, Boroujerdi A, Tigges U, Milner R. Microglia
use multiple mechanisms to mediate interactions with vitro-
nectin; non-essential roles for the highly-expressed alphav-
beta3 and alphavbeta5 integrins. J Neuroinflammation. 2011;
8:157.
51. Hermosilla T, Munoz D, Herrera-Molina R, et al. Direct Thy-
1/alphaVbeta3 integrin interaction mediates neuron to
182 B. Vadasz et al.astrocyte communication. Biochim Biophys Acta. 2008;1783:
1111e1120.
52. Fusi FM, Tamburini C, Mangili F, Montesano M, Ferrari A,
Bronson RA. The expression of alpha v, alpha 5, beta 1, and
beta 3 integrin chains on ejaculated human spermatozoa
varies with their functional state. Mol Hum Reprod. 1996;2:
169e175.
53. Kumpel BM, Sibley K, Jackson DJ, White G, Soothill PW. Ul-
trastructural localization of glycoprotein IIIa (GPIIIa, beta 3
integrin) on placental syncytiotrophoblast microvilli: impli-
cations for platelet alloimmunization during pregnancy.
Transfusion. 2008;48:2077e2086.
54. Konkle BA, Shapiro SS, Asch AS, Nachman RL. Cytokine-
enhanced expression of glycoprotein Ib alpha in human
endothelium. J Biol Chem. 1990;265:19833e19838.
55. Wu G, Essex DW, Meloni FJ, et al. Human endothelial cells in
culture and in vivo express on their surface all four compo-
nents of the glycoprotein Ib/IX/V complex. Blood. 1997;90:
2660e2669.
56. Ware J. Molecular analyses of the platelet glycoprotein Ib-IX-
V receptor. Thromb Haemost. 1998;79:466e478.
57. Snir A, Brenner B, Paz B, Lanir N. Presence of integrin
alpha(IIb)beta 3 in early gestation human trophoblasts:
possible involvement of fibrin as a matrix ligand. Thromb Res.
2010;125:253e256.
58. Berlanga O, Emambokus N, Frampton J. GPIIb (CD41) integrin
is expressed on mast cells and influences their adhesion
properties. Exp Hematol. 2005;33:403e412.
59. Zhou J, Chen H, Li S, et al. Fibroblastic potential of CD41þ
cells in the mouse aorta-gonad-mesonephros region and yolk
sac. Stem Cells Dev. 2012;21:2592e2605.
60. Corbel C, Vaigot P, Salaun J. (alpha)IIb Integrin, a novel
marker for hemopoietic progenitor cells. Int J Dev Biol. 2005;
49:279e284.
61. Boisset JC, Clapes T, Van Der Linden R, Dzierzak E, Robin C.
Integrin alphaIIb (CD41) plays a role in the maintenance of
hematopoietic stem cell activity in the mouse embryonic
aorta. Biol Open. 2013;2:525e532.
62. Rodeghiero F, Ruggeri M. ITP and international guidelines:
what do we know, what do we need? Presse Med. 2014;43(4 Pt
2):e61e67.
63. Bussel JB, Husebekk A, Kaplan C, et al. Pathophysiology and
management of fetal and neonatal alloimmune thrombocy-
topenia (FNAIT). Blood. 2013. in press.
64. Lo E, Deane S. Diagnosis and classification of immune-
mediated thrombocytopenia. Autoimmun Rev. 2014;13:
577e583.
65. Liebman H. Other immune thrombocytopenias. Semin Hema-
tol. 2007;44(4 suppl 5):S24eS34.
66. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP
syndrome: pathogenic and clinical diversity. Blood. 2009;113:
6511e6521.
67. Cines DB, Blanchette VS. Immune thrombocytopenic purpura.
N Engl J Med. 2002;346:995e1008.
68. Abrahamson PE, Hall SA, Feudjo-Tepie M, Mitrani-Gold FS,
Logie J. The incidence of idiopathic thrombocytopenic pur-
pura among adults: a population-based study and literature
review. Eur J Haematol. 2009;83:83e89.
69. Semple JW, Provan D, Garvey MB, Freedman J. Recent prog-
ress in understanding the pathogenesis of immune thrombo-
cytopenia. Curr Opin Hematol. 2010;17:590e595.
70. Beardsley DS, Ertem M. Platelet autoantibodies in immune
thrombocytopenic purpura. Transfus Sci. 1998;19:237e244.
71. Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated
cytotoxicity toward platelets in chronic idiopathic thrombo-
cytopenic purpura. Nat Med. 2003;9:1123e1124.
72. Sayeh E, Sterling K, Speck E, Freedman J, Semple JW. IgG
antiplatelet immunity is dependent on an early innate naturalkiller cell-derived interferon-gamma response that is regu-
lated by CD8þ T cells. Blood. 2004;103:2705e2709.
73. Chow L, Aslam R, Speck ER, et al. A murine model of severe
immune thrombocytopenia is induced by antibody- and CD8þ
T cell-mediated responses that are differentially sensitive to
therapy. Blood. 2010;115:1247e1253.
74. Allen DL, Metcalfe P, Kaplan C, et al. Sensitivity of assays for
the detection of HPA-1a antibodies: results of an international
workshop demonstrating the impact of cation chelation from
integrin alphaIIbbeta3 on three widely used assays. Vox Sang.
2013;105:167e173.
75. Ni H, Li A, Simonsen N, Wilkins JA. Integrin activation by
dithiothreitol or Mn2þ induces a ligand-occupied confor-
mation and exposure of a novel NH2-terminal regulatory
site on the beta1 integrin chain. J Biol Chem. 1998;273:
7981e7987.
76. Ni H, Wilkins JA. Localisation of a novel adhesion blocking
epitope on the human beta 1 integrin chain. Cell Adhes
Commun. 1998;5:257e271.
77. Luo BH, Carman CV, Springer TA. Structural basis of integrin
regulation and signaling. Ann Rev Immunol. 2007;25:619e647.
78. Hynes RO. Integrins: bidirectional, allosteric signaling ma-
chines. Cell. 2002;110:673e687.
79. Wilkins JA, Li A, Ni H, Stupack DG, Shen C. Control of beta1
integrin function. Localization of stimulatory epitopes. J Biol
Chem. 1996;271:3046e3051.
80. Zeng Q, Zhu L, Tao L, et al. Relative efficacy of steroid
therapy in immune thrombocytopenia mediated by anti-
platelet GPIIbIIIa versus GPIbalpha antibodies. Am J Hema-
tol. 2012;87:206e208.
81. Peng J, Ma SH, Liu J, et al. Association of autoantibody
specificity and response to intravenous immunoglobulin G
therapy in immune thrombocytopenia: a multicenter cohort
study. J Thromb Haemost. 2014;12:497e504.
82. Webster ML, Sayeh E, Crow M, et al. Relative efficacy of
intravenous immunoglobulin G in ameliorating thrombocyto-
penia induced by antiplatelet GPIIbIIIa versus GPIbalpha an-
tibodies. Blood. 2006;108:943e946.
83. Chang M, Nakagawa PA, Williams SA, et al. Immune throm-
bocytopenic purpura (ITP) plasma and purified ITP mono-
clonal autoantibodies inhibit megakaryocytopoiesis in vitro.
Blood. 2003;102:887e895.
84. Nieswandt B, Bergmeier W, Rackebrandt K, Gessner JE,
Zirngibl H. Identification of critical antigen-specific mecha-
nisms in the development of immune thrombocytopenic pur-
pura in mice. Blood. 2000;96:2520e2527.
85. Webster ML, Zhu G, Li Y, Ni H. Fc-independent phagocytosis:
implications for intravenous IgG therapy in immune throm-
bocytopenia. Cardiovasc Hematol Disord Drug Targets. 2008;
8:278e282.
86. Li J, van der Wal DE, Zhu L, et al. Fc-independent phagocy-
tosis: implications for IVIG and other therapies in immune-
mediated thrombocytopenia. Cardiovasc Hematol Disord
Drug Targets. 2013;13:50e58.
87. Jansen AJ, Peng J, Zhao HG, Hou M, Ni H. Sialidase inhibition
to increase platelet counts: a new treatment option for
thrombocytopenia. Am J Hematol. 2015;90(5):E94eE95.
88. Li J, van der Wal DE, Zhu G, et al. Platelet desialylation: a
novel mechanism of Fc-independent platelet clearance and a
potential diagnostic biomarker and therapeutic target in
immune thrombocytopenia. Paper presented at: 56th ASH
Annual Meeting; December 4e6, 2014; San Francisco, CA.
89. Li J, Callum JL, Lin Y, Zhou Y, Zhu G, Ni H. Severe platelet
desialylation in a patient with glycoprotein Ib/IX antibody-
mediated immune thrombocytopenia and fatal pulmonary
hemorrhage. Haematologica. 2014;99:e61e63.
90. Shao L, Wu Y, Zhou H, et al. Successful treatment with osel-
tamivir phosphate in a patient with chronic immune
Platelets and platelet alloantigens 183thrombocytopenia positive for anti-GPIb/IX autoantibody.
Platelets. 2014:1e3.
91. Kaplan C. Immune thrombocytopenia in the foetus and the
newborn: diagnosis and therapy. Transfus Clin Biol. 2001;8:
311e314.
92. Bussel JB. Immune thrombocytopenia in pregnancy: autoim-
mune and alloimmune. J Reprod Immunol. 1997;37:35e61.
93. Hachisuga K, Hidaka N, Fujita Y, Fukushima K, Kato K. Can we
predict neonatal thrombocytopenia in offspring of women
with idiopathic thrombocytopenic purpura? Blood Res. 2014;
49:259e264.
94. Webert KE, Mittal R, Sigouin C, Heddle NM, Kelton JG. A retro-
spective 11-year analysis of obstetric patients with idiopathic
thrombocytopenic purpura. Blood. 2003;102:4306e4311.
95. Kutuk MS, Croisille L, Gorkem SB, et al. Fetal intracranial
hemorrhage related to maternal autoimmune thrombocyto-
penic purpura. Childs Nerv Syst. 2014;30:2147e2150.
96. Roberts I, Stanworth S, Murray NA. Thrombocytopenia in the
neonate. Blood Rev. 2008;22:173e186.
97. Murray NA, Roberts IA. Circulating megakaryocytes and their
progenitors in early thrombocytopenia in preterm neonates.
Pediatr Res. 1996;40:112e119.
98. Watts TL, Murray NA, Roberts IA. Thrombopoietin has a pri-
mary role in the regulation of platelet production in preterm
babies. Pediatr Res. 1999;46:28e32.
99. Kaplan C, Ni H, Freedman J. Alloimmune Thrombocytopenia
(CHAPTER 46). In: Michelson AD, ed. Platelets. 3rd ed. San
Diego, CA: Elsevier/Academic Press; 2013:953e970.
100. Bussel JB, Primiani A. Fetal and neonatal alloimmune
thrombocytopenia: progress and ongoing debates. Blood Rev.
2008;22:33e52.
101. Mueller-Eckhardt C, Kiefel V, Grubert A, et al. 348 cases of
suspected neonatal alloimmune thrombocytopenia. Lancet.
1989;1:363e366.
102. Bussel JB, Zabusky MR, Berkowitz RL, McFarland JG. Fetal
alloimmune thrombocytopenia.NEngl JMed. 1997;337:22e26.
103. Kaplan C. Foetal and neonatal alloimmune thrombocytopae-
nia. Orphanet J Rare Dis. 2006;1:39.
104. Harrington WJ, Sprague CC, Minnich V, Moore CV, Aulvin RC,
Dubach R. Immunologic mechanisms in idiopathic and neonatal
thrombocytopenic purpura. Ann Intern Med. 1953;38:433e469.
105. Shulman NR, Aster RH, Pearson HA, Hiller MC. Immuno-
reactions involving platelet. VI. Reactions of maternal iso-
antibodies responsible for neonatal purpura. Differentiation
of a second platelet antigen system. J Clin Invest. 1962;41:
1059e1069.
106. Dreyfus M, Kaplan C, Verdy E, Schlegel N, Durand-Zaleski I,
Tchernia G. Frequency of immune thrombocytopenia in
newborns: a prospective study. Immune Thrombocytopenia
Working Group. Blood. 1997;89:4402e4406.
107. Chakravorty S, Roberts I. How I manage neonatal thrombo-
cytopenia. Br J Haematol. 2012;156:155e162.
108. Herman JH, Jumbelic MI, Ancona RJ, Kickler TS. In utero ce-
rebral hemorrhage in alloimmune thrombocytopenia. Am J
Pediatr Hematol Oncol. 1986;8:312e317.
109. Tiller H, Kamphuis MM, Flodmark O, et al. Fetal intracranial
haemorrhages caused by fetal and neonatal alloimmune
thrombocytopenia: an observational cohort study of 43 cases
from an international multicentre registry. BMJ Open. 2013;3:
e002490.
110. Silva F, Morais S, Sevivas T, Veiga R, Salvado R, Taborda A.
Severe intracranial haemorrhage in neonatal alloimmune
thrombocytopenia. BMJ Case Rep. 2011;2011.
111. Murphy MF, Manley R, Roberts D. Neonatal alloimmune throm-
bocytopenia. Haematologica. 1999;84(suppl EHA-4):110e114.
112. Giovangrandi Y, Daffos F, Kaplan C, Forestier F, Mac Aleese J,
Moirot M. Very early intracranial haemorrhage in alloimmune
fetal thrombocytopenia. Lancet. 1990;336:310.113. Bussel JB, Berkowitz RL, Hung C, et al. Intracranial hemor-
rhage in alloimmune thrombocytopenia: stratified manage-
ment to prevent recurrence in the subsequent affected fetus.
Am J Obstet Gynecol. 2010;203. e131e114.
114. Butros LJ, Bussel JB. Intracranial hemorrhage in immune
thrombocytopenic purpura: a retrospective analysis. J
Pediatr Hematol Oncol. 2003;25:660e664.
115. von Lindern JS, van den Bruele T, Lopriore E, Walther FJ.
Thrombocytopenia in neonates and the risk of intraventric-
ular hemorrhage: a retrospective cohort study. BMC Pediatr.
2011;11:16.
116. Kjeldsen-Kragh J, Killie MK, Tomter G, et al. A screening and
intervention program aimed to reduce mortality and serious
morbidity associated with severe neonatal alloimmune
thrombocytopenia. Blood. 2007;110:833e839.
117. Davoren A, McParland P, Barnes CA, Murphy WG. Neonatal
alloimmune thrombocytopenia in the Irish population: a
discrepancy between observed and expected cases. J Clin
Pathol. 2002;55:289e292.
118. Bertrand G, Petermann R, Kaplan C. Prediction of IVIG
treatment efficiency in fetal/neonatal alloimmune thrombo-
cytopenia. Blood. 2014;124:654e655.
119. Murphy MF, Hambley H, Nicolaides K, Waters AH. Severe
fetomaternal alloimmune thrombocytopenia presenting with
fetal hydrocephalus. Prenat Diagn. 1996;16:1152e1155.
120. Bertrand G, Drame M, Martageix C, Kaplan C. Prediction of
the fetal status in non-invasive management of alloimmune
thrombocytopenia. Blood. 2011;117:3209e3213.
121. Forestier F, Daffos F, Galacteros F, Bardakjian J, Rainaut M,
Beuzard Y. Hematological values of 163 normal fetuses between
18 and 30 weeks of gestation. Pediatr Res. 1986;20:342e346.
122. Chen P, Li C, Lang S, et al. Animal model of fetal and neonatal
immune thrombocytopenia: role of neonatal Fc receptor in
the pathogenesis and therapy. Blood. 2010;116:3660e3668.
123. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor
comes of age. Nat Rev Immunol. 2007;7:715e725.
124. McMillan R, Longmire RL, Tavassoli M, Armstrong S,
Yelenosky R. In vitro platelet phagocytosis by splenic leuko-
cytes in idiopathic thrombocytopenic purpura. N Engl J Med.
1974;290:249e251.
125. von dem Borne AE, Decary F. ICSH/ISBT working party on
platelet serology. Nomenclature of platelet-specific antigens.
Vox Sang. 1990;58:176.
126. Metcalfe P, Watkins NA, Ouwehand WH, et al. Nomenclature
of human platelet antigens. Vox Sang. 2003;85:240e245.
127. Santoso S, Kiefel V, Richter IG, et al. A functional platelet
fibrinogen receptor with a deletion in the cysteine-rich repeat
region of the beta(3) integrin: the Oe(a) alloantigen in neonatal
alloimmune thrombocytopenia. Blood. 2002;99:1205e1214.
128. Curtis BR, McFarland JG. Human platelet antigens e 2013. Vox
Sang. 2014;106:93e102.
129. Salomon O, Rosenberg N. Predicting risk severity and response
of fetal neonatal alloimmune thrombocytopenia. Br J Hae-
matol. 2013;162:304e312.
130. Newman PJ, Derbes RS, Aster RH. The human
platelet alloantigens, PlA1 and PlA2, are associated with a
leucine33/proline33 amino acid polymorphism in membrane
glycoprotein IIIa, and are distinguishable by DNA typing. J Clin
Invest. 1989;83:1778e1781.
131. Knight M, Pierce M, Allen D, et al. The incidence and out-
comes of fetomaternal alloimmune thrombocytopenia: a UK
national study using three data sources. Br J Haematol. 2011;
152:460e468.
132. Ramsey G, Salamon DJ. Frequency of PLA1 in blacks. Trans-
fusion. 1986;26:531e532.
133. Brouk H, Halle L, Bertrand G, Neche FZ, Ouelaa H, Kaplan C.
Human platelet antigen allele frequencies in different
Algerian populations. Tissue Antigens. 2010;75:673e678.
184 B. Vadasz et al.134. Mueller-Eckhardt C, Santoso S, Kiefel V. Platelet alloantigens
e molecular, genetic, and clinical aspects. Vox Sang. 1994;
67(suppl 3):89e93.
135. Santoso S, Kiefel V, Masri R, Mueller-Eckhardt C. Frequency of
platelet-specific antigens among Indonesians. Transfusion.
1993;33:739e741.
136. Smaoui M, Hadjkacem B, Ben Amor I, et al. Allelic poly-
morphisms of human platelets-specific alloantigens in South
Tunisian population. Hematology. 2013;18:365e369.
137. Koh Y, Ishii H, Amakishi E, et al. The first two cases of
neonatal alloimmune thrombocytopenia associated with the
low-frequency platelet antigen HPA-21bw (Nos) in Japan.
Transfusion. 2012;52:1468e1475.
138. Ghevaert C, Rankin A, Huiskes E, et al. Alloantibodies against
low-frequency human platelet antigens do not account for a
significant proportion of cases of fetomaternal alloimmune
thrombocytopenia: evidence from 1054 cases. Transfusion.
2009;49:2084e2089.
139. Rousseau J, Goldman M, David M. HPA-5b (Bra) neonatal
alloimmune thrombocytopenia in Quebec: incidence and
clinical outcome in 31 cases. Transfusion. 2004;44:844e848.
140. Goldman M, Trudel E, Richard L, Khalife S, Spurll GM.
Neonatal alloimmune thrombocytopenia due to anti-HPA-2b
(anti-Koa). Immunohematology/American Red Cross. 2003;
19:43e46.
141. Al-Sheikh IH, Khalifa M, Rahi A, Qadri MI, Al Abad K. A rare
case of neonatal alloimmune thrombocytopenia due to ANTI-
HPA-2b. Ann Saudi Med. 1998;18:547e549.
142. Kaplan C, Porcelijn L, Vanlieferinghen P, et al. Anti-HPA-9bw
(Maxa) fetomaternal alloimmunization, a clinically severe
neonatal thrombocytopenia: difficulties in diagnosis and
therapy and report on eight families. Transfusion. 2005;45:
1799e1803.
143. Glade-Bender J, McFarland JG, Kaplan C, Porcelijn L,
Bussel JB. Anti-HPA-3A induces severe neonatal alloimmune
thrombocytopenia. J Pediatr. 2001;138:862e867.
144. Peterson JA, Pechauer SM, Gitter ML, et al. New platelet
glycoprotein polymorphisms causing maternal immunization
and neonatal alloimmune thrombocytopenia. Transfusion.
2012;52:1117e1124.
145. Sachs UJ, Eva O, Giptner A, Bein G, Peterson A, Santoso S. A
new low-frequency polymorphism on platelet glycoprotein
IIIa (sec) is associated with neonatal alloimmune thrombo-
cytopenia and with impaired GP IIb/IIIa function. Vox Sang.
2010;99(suppl 2):19e23.
146. Gerhardt A, Howe N, Krussel JS, Scharf RE, Zotz RB. Elevated
lipoprotein(a) levels and homozygous human platelet antigen
1b (HPA-1b) genotype are risk factors for intrauterine growth
restriction (IUGR). J Thromb Thrombolysis. 2014;37:107e117.
147. Bray PF. Integrin polymorphisms as risk factors for throm-
bosis. Thromb Haemost. 1999;82:337e344.
148. Curtis BR, Ali S, Glazier AM, Ebert DD, Aitman TJ, Aster RH.
Isoimmunization against CD36 (glycoprotein IV): description
of four cases of neonatal isoimmune thrombocytopenia and
brief review of the literature. Transfusion. 2002;42:
1173e1179.
149. Xu X, Ye X, Xia W, et al. Studies on CD36 deficiency in South
China: two cases demonstrating the clinical impact of anti-
CD36 antibodies. Thromb Haemost. 2013;110:1199e1206.
150. Ikeda H, Mitani T, Ohnuma M, et al. A new platelet-specific
antigen, Naka, involved in the refractoriness of HLA-
matched platelet transfusion. Vox Sang. 1989;57:213e217.
151. Kjeldsen-Kragh J, Ni H, Skogen B. Towards a prophylactic
treatment of HPA-related foetal and neonatal alloimmune
thrombocytopenia. Curr Opin Hematol. 2012;19:469e474.
152. Chakraborty C, Gleeson LM, McKinnon T, Lala PK. Regulation
of human trophoblast migration and invasiveness. Can J
Physiol Pharmacol. 2002;80:116e124.153. Ni H, Chen P, Spring CM, et al. A novel murine model of fetal
and neonatal alloimmune thrombocytopenia: response to
intravenous IgG therapy. Blood. 2006;107:2976e2983.
154. Wu S, Maslanka K, Gorski J. An integrin polymorphism that
defines reactivity with alloantibodies generates an anchor for
MHC class II peptide binding: a model for unidirectional
alloimmune responses. J Immunol. 1997;158:3221e3226.
155. Loewenthal R, Rosenberg N, Kalt R, et al. Compound het-
erozygosity of HLA-DRB3*01:01 and HLA-DRB4*01:01 as a po-
tential predictor of fetal neonatal alloimmune
thrombocytopenia. Transfusion. 2013;53:344e352.
156. Li C, Chen P, Vadasz B, et al. Co-stimulation with LPS or Poly I:
C markedly enhances the anti-platelet immune response and
severity of fetal and neonatal alloimmune thrombocytopenia.
Thromb Haemost. 2013;110:1250e1258.
157. Mohapatra S, Cao Y, Ni H, Salo D. In pursuit of the “holy grail”:
recombinant allergens and peptides as catalysts for the
allergen-specific immunotherapy. Allergy. 1995;50(25 suppl):
37e44.
158. Xu W, Banchereau J. The antigen presenting cells instruct
plasma cell differentiation. Front Immunol. 2014;4:504.
159. Blanchette VS, Chen L, de Friedberg ZS, Hogan VA, Trudel E,
Decary F. Alloimmunization to the PlA1 platelet antigen: re-
sults of a prospective study. Br J Haematol. 1990;74:209e215.
160. Williamson LM, Hackett G, Rennie J, et al. The natural history
of fetomaternal alloimmunization to the platelet-specific
antigen HPA-1a (PlA1, Zwa) as determined by antenatal
screening. Blood. 1998;92:2280e2287.
161. Kamphuis MM, Oepkes D. Fetal and neonatal alloimmune
thrombocytopenia: prenatal interventions. Prenat Diagn.
2011;31:712e719.
162. Bussel J. Diagnosis and management of the fetus and neonate
with alloimmune thrombocytopenia. J Thromb Haemost.
2009;7(suppl 1):253e257.
163. Vinograd CA, Bussel JB. Antenatal treatment of fetal alloim-
mune thrombocytopenia: a current perspective. Haemato-
logica. 2010;95:1807e1811.
164. Paidas MJ, Berkowitz RL, Lynch L, et al. Alloimmune throm-
bocytopenia: fetal and neonatal losses related to cordo-
centesis. Am J Obstet Gynecol. 1995;172(2 Pt 1):475e479.
165. Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, et al.
Transcription factor NF-E2 is required for platelet formation
independent of the actions of thrombopoietin/MGDF in
megakaryocyte development. Cell. 1995;81:695e704.
166. Palumbo JS, Zogg M, Talmage KE, Degen JL, Weiler H,
Isermann BH. Role of fibrinogen- and platelet-mediated he-
mostasis in mouse embryogenesis and reproduction. J Thromb
Haemost. 2004;2:1368e1379.
167. Kiefel V, Bassler D, Kroll H, et al. Antigen-positive platelet
transfusion in neonatal alloimmune thrombocytopenia (NAIT).
Blood. 2006;107:3761e3763.
168. Kaplan C, Murphy MF, Kroll H, Waters AH. Feto-maternal
alloimmune thrombocytopenia: antenatal therapy with IvIgG
and steroidsemore questions than answers. European Work-
ing Group on FMAIT. Br J Haematol. 1998;100:62e65.
169. Pacheco LD, Berkowitz RL, Moise Jr KJ, Bussel JB,
McFarland JG, Saade GR. Fetal and neonatal alloimmune
thrombocytopenia: a management algorithm based on risk
stratification. Obstet Gynecol. 2011;118:1157e1163.
170. Bertrand G, Kaplan C. How do we treat fetal and neonatal
alloimmune thrombocytopenia? Transfusion. 2014;54:
1698e1703.
171. Bussel JB, Zacharoulis S, Kramer K, McFarland JG, Pauliny J,
Kaplan C. Clinical and diagnostic comparison of neonatal
alloimmune thrombocytopenia to non-immune cases of
thrombocytopenia. Pediatr Blood Cancer. 2005;45:176e183.
172. Nishimoto T, Satoh T, Simpson EK, Ni H, Kuwana M. Predom-
inant autoantibody response to GPIb/IX in a regulatory T-cell-
Platelets and platelet alloantigens 185deficient mouse model for immune thrombocytopenia.
J Thromb Haemost. 2013;11:369e372.
173. Oyaizu N, Yasumizu R, Miyama-Inaba M, et al. (NZW x BXSB)F1
mouse. A new animal model of idiopathic thrombocytopenic
purpura. J Exp Med. 1988;167:2017e2022.
174. Dekel B, Marcus H, Shenkman B, et al. Human/BALB radiation
chimera engrafted with splenocytes from patients with idio-
pathic thrombocytopenic purpura produce human platelet
antibodies. Immunology. 1998;94:410e416.
175. Hansen RJ, Balthasar JP. Pharmacokinetics, pharmacody-
namics, and platelet binding of an anti-glycoprotein IIb/IIIa
monoclonal antibody (7E3) in the rat: a quantitative rat
model of immune thrombocytopenic purpura. J Pharmacol
Exp Ther. 2001;298:165e171.
176. Hosono M, Sone N, Endo K, et al. Kinetics of platelets in dogs
with thrombocytopenia induced by antiglycoprotein IIb/IIIa
receptor monoclonal antibody. Nucl Med Biol. 1995;22:
71e76.
177. Coetzee LM, Pieters H, van Wyk V, et al. The effect of
monoclonal anti-human-platelet antibodies on platelet ki-
netics in a baboon model: IgG subclass dependency. Thromb
Haemost. 2000;83:148e156.
178. Leytin V, Mykhaylov S, Starkey AF, et al. Intravenous immu-
noglobulin inhibits anti-glycoprotein IIb-induced platelet
apoptosis in a murine model of immune thrombocytopenia. Br
J Haematol. 2006;133:78e82.
179. Crow AR, Song S, Semple JW, Freedman J, Lazarus AH. IVIg
inhibits reticuloendothelial system function and amelio-
rates murine passive-immune thrombocytopenia indepen-
dent of anti-idiotype reactivity. Br J Haematol. 2001;115:
679e686.180. Ghevaert C, Wilcox DA, Fang J, et al. Developing recombinant
HPA-1a-specific antibodies with abrogated Fcgamma receptor
binding for the treatment of fetomaternal alloimmune
thrombocytopenia. J Clin Invest. 2008;118:2929e2938.
181. Bakchoul T, Boylan B, Sachs UJ, et al. Blockade of maternal
anti-HPA-1a-mediated platelet clearance by an HPA-1a
epitope-specific F(ab’) in an in vivo mouse model of alloim-
mune thrombocytopenia. Transfusion. 2009;49:265e270.
182. Lang S, Yang H, Boyd S, et al. Impaired angiogenesis con-
tributes to pathogenesis of fetal and neonatal immune
thrombocytopenia. J Thromb Haemost. 2011. XXIII Congress
of the International Society on Thrombosis and Haemostasis.
183. Yougbare´ I, Lang S, Yang H, et al. Maternal anti-platelet b3
integrins impair angiogenesis and cause intracranial hemor-
rhage. J Clin Invest. 2015. In press.
184. Firan M, Bawdon R, Radu C, et al. The MHC class I-related
receptor, FcRn, plays an essential role in the maternofetal
transfer of gamma-globulin in humans. Int Immunol. 2001;13:
993e1002.
185. Killie MK, Husebekk A, Kjeldsen-Kragh J, Skogen B. A pro-
spective study of maternal anti-HPA 1a antibody level as a
potential predictor of alloimmune thrombocytopenia in the
newborn. Haematologica. 2008;93:870e877.
186. Kjeldsen-Kragh J, Skogen B. Mechanisms and prevention of
alloimmunization in pregnancy. Obstet Gynecol Surv. 2013;
68:526e532.
187. Tiller H, Killie MK, Chen P, et al. Toward a prophylaxis against
fetal and neonatal alloimmune thrombocytopenia: induction
of antibody-mediated immune suppression and prevention of
severe clinical complications in a murine model. Transfusion.
2012;52:1446e1457.
